Xin Lang Cai Jing·2025-10-13 17:37Group 1 - The core point of the news is that Junshi Biosciences has experienced a decline in stock price, dropping 1.77% to 38.91 CNY per share, with a total market capitalization of 39.949 billion CNY and a cumulative drop of 6.15% over the past three days [1] - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [1] - The company is headquartered in Shanghai, with additional offices in Hong Kong, and was listed on July 15, 2020 [1] Group 2 - From the perspective of fund holdings, only one fund under Huatai-PineBridge has a significant position in Junshi Biosciences, with a reduction of 10.87 thousand shares in the second quarter, now holding 166.23 thousand shares, representing 4.89% of the fund's net value [2] - The fund, Huatai-PineBridge CSI Precision Medicine Index (LOF) A, has reported a floating loss of approximately 116.36 thousand CNY today and a total floating loss of 423.89 thousand CNY during the three-day decline [2] - The fund was established on January 21, 2016, with a current scale of 778 million CNY and has achieved a year-to-date return of 41.21% [2]